

PRECISION ONCOLOGY BEYOND EGFR/ALK FOR NSCLC IN 2023: TEST, TARGET, MANAGE

Chairs

Solange Peters, Lausanne, Switzerland

Benjamin Besse, Villejuif, France

THURSDAY, 30 MARCH 2023

09:15 – 10:45 CEST, AUDITORIUM 4

09:15	Introduction: Summary data on the ESMO Survey on Biomolecular Technology Availability	Solange Peters, Lausanne, Switzerland
09:20	Current indications of precision therapeutics in advanced oncogene-addicted NSCLC beyond EGFR and ALK: Efficacy, safety, value	Benjamin Besse, Villejuif, France
09:35	The quest for optimal integration of biomarker testing by tissue NGS in the care pathway: Analytics, availability and reporting of actionable vs non-actionable aberrations	Javier Hernandez Losa, Barcelona, Spain
09:50	Q&A	All speakers
10:00	The quest for optimal positioning of liquid biopsies in the workup of patients with NSCLC: When, for what and how often	Umberto Malapelle, Naples, Italy
10:15	Highlighting the value of Molecular Tumour Boards: Presentation of two patient cases with oncogene-addicted NSCLC, summary of clinical evidence and insights in molecular profiling/interpretation	Simon Ekman, Solna, Sweden
10:30	Q&A and discussion	All speakers
10:40	Concluding remarks	Benjamin Besse, Villejuif, France

This educational activity is provided by ESMO
and supported by Eli Lilly and Company.

Lilly

